Collegium Pharmaceutical vs Supernus Pharmaceuticals
Collegium Pharmaceutical and Supernus Pharmaceuticals are similar in size: $781m and $719m of revenue in their latest fiscal years. Collegium Pharmaceutical grew faster (23.6% against 8.6%). Collegium Pharmaceutical kept more of each dollar of sales as profit: a net margin of 8.1% against -5.4%. Supernus Pharmaceuticals carries less debt relative to equity (0.0% against 79.0%).
| Latest fiscal year | Collegium PharmaceuticalCOLL, 2025 | Supernus PharmaceuticalsSUPN, 2025 |
|---|---|---|
| Revenue | $781m | $719m |
| Revenue growth | 23.6% | 8.6% |
| Net income | $62.9m | −$38.5m |
| Operating margin | 23.0% | -8.7% |
| Net margin | 8.1% | -5.4% |
| Return on equity | 23.7% | -3.7% |
| Free cash flow | $328m | $46.0m |
| Cash | $231m | $128m |
| Total debt | $238m | $0 |
| Debt to equity | 79.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $25.1m | — |
| Employees | 423 | 778 |
| Market value | $770m | $2.44bn |
| Price vs our value range | Below our value range | Below our value range |
| Moat score | 48 (Moderate) | 69 (Moderate) |
| Insider trades, 12 months | 0 buys, 14 sales | 0 buys, 20 sales |